PTGFRN and neoplasm: Toward improved tumor targetability, IL12 was displayed on exosome surface via fusion with the exosome surface protein PTGFRN, and the resultant exosome (exoIL12) conveyed tumor-restricted pharmacology that led to prolonged tumor retention and immune memory (141).